Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Phase III
Awakn Life SciencesCSE: AWKN
2 Drug Candidates
UK-based biopharmaceutical company developing ketamine and esketamine-based treatments for alcohol use disorder and addiction. AWKN-001 (IV ketamine combined with cognitive behavioural therapy) is in Phase 3 clinical trials in the UK for alcohol use disorder. AWKN-002, an esketamine oral thin film formulation, is in pre-IND development for the US market.
Drug Pipeline
2AWKN-001
KetaminePhase III
IV ketamine combined with manualised cognitive behavioural therapy (CBT) for alcohol use disorder. Phase 3 trial ongoing in the UK.
AWKN-002
EsketamineDiscovery
Esketamine oral thin film formulation for alcohol use disorder. Pre-IND development for the US market.
Quick Facts
- Type
- Public Biotech
- Founded
- 2020
- Ticker
- CSE: AWKN
- Lead Stage
- Phase III
- Website
- Visit